A recent study led by experts from the University of Manchester suggests that introducing a UK-wide sampling program alongside the existing cervical smear test could help remove the barriers that prevent people from attending cervical screening.
Pathologists play a crucial part in patient treatment, particularly in cancer care. However, the field faces challenges such as resource shortages, workflow inefficiencies, and increasing complexity. To adapt, pathology departments are embracing digital solutions to enhance diagnostics and support the transformation of healthcare.
Professor David Sebag-Montefiore outlines the profound impact of radiotherapy research. Through global trials and personalised approaches, innovation advances cancer care. Collaborative efforts ensure patient-centred treatments, paving the way for smarter, kinder therapies and a future of precision oncology.
Trevor Graham, Professor of Genomics and Evolution and the Director of the Centre for Evolution and Cancer at the Institute of Cancer Research, London, describes efforts to incorporate genome sequencing for cancer detection and treatment.
Cancer cells are masters of disguise, evading immune destruction through cunning mechanisms. Groundbreaking research reveals a novel tactic: mitochondrial transfer. Cancer cells cripple immune cells by donating their damaged mitochondria, hindering the immune response and fostering tumour growth.
The UK government is investing £82.6 million in groundbreaking research to harness the power of artificial intelligence (AI) to transform cancer care and accelerate drug discovery.
A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient. Researchers identified a RUFY1-RET fusion, highlighting the need for advanced genetic testing to guide treatment strategies and combat evolving resistance.
AI-powered pathology presents the NHS with a unique opportunity to enhance cancer detection. Paige AI explains how its tools can facilitate quicker diagnostics and improve cost efficiency within the UK’s health system.
Tarlatamaba, a new treatment for adult patients with small cell lung cancer (SCLC), has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA).
Infections are the second leading cause of death in cancer patients, after the cancer itself; Zisis Kozlakidis and Shalini Jayasekar Zurn discuss the challenges surrounding the interplay between cancer and antimicrobial resistance (AMR).
